DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Women’s Health Review and Outlook 2011” report to their offering.
The global women’s health market, valued at $20 billion in 2009, is dominated by the United States. Hormonal contraceptives is one of the leading categories within the market. Bayer’s Yaz, Yasmin, and Yasminelle were the top selling drugs in that category for 2009 with combined sales of $1.78 billion.
The women’s health-care market segment has a strong demand for novel therapeutics and improved diagnostics. Therapeutic categories gaining increased attention within this market include breast cancer, oral contraceptives, hormone therapy for menopause, heart disease, rheumatoid arthritis, and gynecologic infections including STD’s and osteoporosis. Diagnostic imaging applications with increasing market potential include bone densitometry, breast biopsy and imaging, OB/GYN ultrasound imaging, and fetal & neonatal monitoring – these represent almost half of the women’s health market segment in terms of cost.
Promising treatments in late-stage clinical development include Aprela, in development by Pfizer Inc., and Menerba, in development by Bionovo Inc. Both are designed to treat the vasomotor symptoms associated with menopause. Aprela is intended as an alternative to combination estrogen and progestin therapies. Menerba has a targeted mechanism of action that activates only the estrogen receptor beta pathway, which is associated with hot flashes. Unlike hormone therapy, Menerba does not activate the estrogen receptor alpha (ERa) pathway, known to be implicated in both breast and uterine cancer formation.